<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03859739</url>
  </required_header>
  <id_info>
    <org_study_id>8558-002</org_study_id>
    <secondary_id>MK-8558-002</secondary_id>
    <nct_id>NCT03859739</nct_id>
  </id_info>
  <brief_title>Safety, Tolerability, Pharmacokinetics, and Anti-Retroviral Activity of MK-8558 Monotherapy in Anti-Retroviral-Naïve HIV-1 Infected Participants (MK-8558-002)</brief_title>
  <official_title>A Single-Dose Clinical Trial to Study the Safety, Tolerability, Pharmacokinetics, and Anti-Retroviral Activity of MK-8558 Monotherapy in Anti-Retroviral-Naïve HIV-1 Infected Participants</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Merck Sharp &amp; Dohme Corp.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Merck Sharp &amp; Dohme Corp.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>Yes</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate the safety, tolerability, pharmacokinetics, and&#xD;
      anti-retroviral activity of MK-8558 monotherapy in anti-retroviral-naïve human&#xD;
      immunodeficiency virus type 1 (HIV-1) infected participants. The primary hypothesis is that&#xD;
      at a dose that exhibits an acceptable safety and tolerability profile, MK-8558 has superior&#xD;
      anti-retroviral activity compared to historical placebo data.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">April 26, 2019</start_date>
  <completion_date type="Actual">May 29, 2020</completion_date>
  <primary_completion_date type="Actual">May 29, 2020</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Sequential Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change From Baseline in Plasma HIV-1 Ribonucleic Acid (RNA) Concentration</measure>
    <time_frame>Baseline and 168 hours post-dose</time_frame>
    <description>Plasma was collected at baseline and at 168 hours post-dose to determine the change from baseline in HIV-1 ribonucleic acid (RNA) concentration. The log10 plasma HIV-RNA was measured and analyzed based on a longitudinal data analysis (LDA) model containing fixed effects for dose level and time.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of Participants Experiencing ≥1 Adverse Event (AE)</measure>
    <time_frame>Up to 35 days post-dose</time_frame>
    <description>An Adverse Event (AE) is any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. An AE can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease (new or exacerbated) temporally associated with the use of a study intervention.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of Participants Who Discontinued From the Study Due to an AE</measure>
    <time_frame>Up to 35 days post-dose</time_frame>
    <description>An AE is any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. An AE can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease (new or exacerbated) temporally associated with the use of a study intervention.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Area Under the Concentration-Time Curve From 0 to 168 Hours (AUC0-168) for MK-8558 in Plasma</measure>
    <time_frame>Pre-dose and 0.5, 1, 1.5, 2, 3, 4, 5, 6, 8, 12, 24, 48, 72, 120, 168 hours post-dose</time_frame>
    <description>Plasma was collected from pre-dose up to 168 hours post-dose in order to determine the AUC0-168 for MK-8558. Data were natural log transformed and analyzed based on a linear model containing a fixed effect for dose level.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Area Under the Concentration-Time Curve From 0 up to the Last Quantifiable Time-Point (AUC0-last) for MK-8558 in Plasma</measure>
    <time_frame>Pre-dose and 0.5, 1, 1.5, 2, 3, 4, 5, 6, 8, 12, 24, 48, 72, 120, 168, 240, 336, 504 hours post-dose</time_frame>
    <description>Plasma was collected from pre-dose up to 504 hours post-dose in order to determine the AUC0-last for MK-8558. Data were natural log transformed and analyzed based on a linear model containing a fixed effect for dose level.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Area Under the Concentration-Time Curve From 0 to Infinity (AUC0-inf) for MK-8558 in Plasma</measure>
    <time_frame>Pre-dose and 0.5, 1, 1.5, 2, 3, 4, 5, 6, 8, 12, 24, 48, 72, 120, 168, 240, 336, 504 hours post-dose</time_frame>
    <description>Plasma was collected from pre-dose up to 504 hours post-dose in order to determine the AUC0-inf for MK-8558. Data were natural log transformed and analyzed based on a linear model containing a fixed effect for dose level.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Maximum Observed Concentration (Cmax) for MK-8558 in Plasma</measure>
    <time_frame>Pre-dose and 0.5, 1, 1.5, 2, 3, 4, 5, 6, 8, 12, 24, 48, 72, 120, 168, 240, 336, 504 hours post-dose</time_frame>
    <description>Plasma was collected from pre-dose up to 504 hours post-dose in order to determine the Cmax for MK-8558. Data were natural log transformed and analyzed based on a linear model containing a fixed effect for dose level.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to Maximum Observed Concentration (Tmax) for MK-8558 in Plasma</measure>
    <time_frame>Pre-dose and 0.5, 1, 1.5, 2, 3, 4, 5, 6, 8, 12, 24, 48, 72, 120, 168, 240, 336, 504 hours post-dose</time_frame>
    <description>Plasma was collected from pre-dose up to 504 hours post-dose in order to determine the Tmax for MK-8558. Data were natural log transformed and analyzed based on a linear model containing a fixed effect for dose level.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Concentration at 168 Hours Post-Dose (C168hr) for MK-8558 in Plasma</measure>
    <time_frame>168 hours post-dose</time_frame>
    <description>Plasma was collected at 168 hours post-dose in order to determine the C168hr for MK-8558. Data were natural log transformed and analyzed based on a linear model containing a fixed effect for dose level.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Apparent Clearance (CL/F) for MK-8558</measure>
    <time_frame>Pre-dose and 0.5, 1, 1.5, 2, 3, 4, 5, 6, 8, 12, 24, 48, 72, 120, 168, 240, 336, 504 hours post-dose</time_frame>
    <description>Plasma was collected from pre-dose up to 504 hours post-dose in order to determine the CL/F for MK-8558. Data were natural log transformed and analyzed based on a linear model containing a fixed effect for dose level.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Apparent Volume of Distribution (Vz/F) for MK-8558</measure>
    <time_frame>Pre-dose and 0.5, 1, 1.5, 2, 3, 4, 5, 6, 8, 12, 24, 48, 72, 120, 168, 240, 336, 504 hours post-dose</time_frame>
    <description>Plasma was collected from pre-dose up to 504 hours post-dose in order to determine the Vz/F for MK-8558. Data were natural log transformed and analyzed based on a linear model containing a fixed effect for dose level.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Terminal Half Life (t1/2) for MK-8558</measure>
    <time_frame>Pre-dose and 0.5, 1, 1.5, 2, 3, 4, 5, 6, 8, 12, 24, 48, 72, 120, 168, 240, 336, 504 hours post-dose</time_frame>
    <description>Plasma was collected from pre-dose up to 504 hours post-dose in order to determine the t1/2 for MK-8558. Data were natural log transformed and analyzed based on a linear model containing a fixed effect for dose level.</description>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">21</enrollment>
  <condition>HIV-1 Infection</condition>
  <arm_group>
    <arm_group_label>Panel A. MK-8558 400 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Single oral dose of MK-8558 administered at 400 mg following a 10-hour fast.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Panel B. MK-8558 at dose level 2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Single oral dose of MK-8558 administered at dose level 2 following a 10-hour fast. Dose level 2 shall not exceed 900 mg. Per protocol, dose will be selected following review of data from panel A.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Panel C. MK-8558 at dose level 3</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Single oral dose of MK-8558 administered at dose level 3 following a 10-hour fast. Dose level 3 shall not exceed 1600 mg. Per protocol, dose will be selected following review of data from panel B.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Panel D. MK-8558 at dose level 4</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Single oral dose of MK-8558 administered at dose level 4 following a low-fat breakfast. Dose level 4 shall not exceed 1600 mg. Per protocol, Panel D is optional pending results of Panels A-C, and dose will be selected following review of data from panel C.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>MK-8558</intervention_name>
    <description>Single dose of MK-8558 administered as a tablet at a dose up to 1600 mg.</description>
    <arm_group_label>Panel A. MK-8558 400 mg</arm_group_label>
    <arm_group_label>Panel B. MK-8558 at dose level 2</arm_group_label>
    <arm_group_label>Panel C. MK-8558 at dose level 3</arm_group_label>
    <arm_group_label>Panel D. MK-8558 at dose level 4</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Other than having HIV infection, is in good health based on medical history, physical&#xD;
             examination, vital sign (VS) measurements, and laboratory safety tests, at the&#xD;
             pre-study (screening) visit and/or prior to administration of the study drug&#xD;
&#xD;
          -  Is documented as being HIV-1 positive&#xD;
&#xD;
          -  Has a screening plasma HIV-1 ribonucleic acid (RNA) ≥ 2,500 copies/mL within 30 days&#xD;
             prior to the treatment phase of this study&#xD;
&#xD;
          -  Has a screening plasma cluster of differentiation 4+ (CD4+) T-cell count of &gt;200/mm^3&#xD;
&#xD;
          -  Is antiretroviral therapy (ART)-naïve&#xD;
&#xD;
          -  Is willing to receive no other ART prior to Day 11 post-dose of the trial, unless the&#xD;
             physician/Investigator believes that there is a strong indication to start ART before&#xD;
             Day 11&#xD;
&#xD;
          -  Has a Body Mass Index (BMI) ≤35 kg/m^2&#xD;
&#xD;
          -  Males must agree to abstinence, or barrier contraception plus partner contraception,&#xD;
             unless confirmed to be azoospermic due to vasectomy or medical cause, for at least 35&#xD;
             days after the last dose of MK-8558&#xD;
&#xD;
          -  Females must not be pregnant or breastfeeding, and must be a woman of nonchildbearing&#xD;
             potential, or a woman of childbearing potential using highly effective birth control&#xD;
             with low user dependency or who is abstinent on a long-term and persistent basis&#xD;
             during the intervention period and at least 35 days after the last dose of study&#xD;
             medication&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Has acute (primary) HIV-1 infection&#xD;
&#xD;
          -  Has a history of clinically significant endocrine, gastrointestinal, cardiovascular,&#xD;
             hematological, hepatic (with the exception of Gilbert's disease), immunological&#xD;
             (outside of HIV-1 infection), renal, respiratory, genitourinary, or major neurological&#xD;
             (including stroke and chronic seizures) abnormalities or diseases&#xD;
&#xD;
          -  Is mentally or legally incapacitated or has a history of a clinically significant&#xD;
             psychiatric disorder (with the exception of situational depression) of the last 5&#xD;
             years&#xD;
&#xD;
          -  Has a history of cancer unless disease is adequately treated and deemed &quot;cured&quot;&#xD;
&#xD;
          -  Has an estimated creatinine clearance (CrCl) ≤ 90 mL/min&#xD;
&#xD;
          -  Has a history of significant multiple and/or severe allergies, or has had an&#xD;
             anaphylactic reaction or significant intolerability to prescription or&#xD;
             non-prescription drugs or food, or has hereditary galactose intolerance, lactase&#xD;
             deficiency, or glucose-galactose malabsorption&#xD;
&#xD;
          -  Is positive for hepatitis B surface antigen&#xD;
&#xD;
          -  Has a history of chronic hepatitis C unless there has been documented cure&#xD;
&#xD;
          -  Had major surgery, donated or lost 1 unit of blood (approximately 500 mL) within 4&#xD;
             weeks prior to the pre-study (screening) visit&#xD;
&#xD;
          -  Is unable to refrain from or anticipates the use of any medication, including&#xD;
             prescription and nonprescription drugs or herbal remedies beginning approximately 2&#xD;
             weeks (or 5 half-lives) prior to administration of the initial dose of study drug,&#xD;
             throughout the study, until the post-study visit. There may be certain medications&#xD;
             that are permitted&#xD;
&#xD;
          -  Has participated in another investigational study within 4 weeks (or 5 half-lives,&#xD;
             whichever is greater) prior to the pre-study (screening) visit. The window will be&#xD;
             derived from the date of the last visit in the previous study&#xD;
&#xD;
          -  Is under the age of legal consent or not capable of giving consent&#xD;
&#xD;
          -  Has been committed to an institution by way of official or judicial order&#xD;
&#xD;
          -  Is an excessive smoker (i.e., more than 10 cigarettes/day) and is unwilling to&#xD;
             restrict smoking to ≤10 cigarettes per day&#xD;
&#xD;
          -  Consumes more than 3 glasses of alcoholic beverages (1 glass is approximately&#xD;
             equivalent to: beer [354 mL/12 ounces], wine [118 mL/4 ounces], or distilled spirits&#xD;
             [29.5 mL/1 ounce]) per day. Participants who consume 4 glasses of alcoholic beverages&#xD;
             per day may be enrolled at the discretion of the investigator&#xD;
&#xD;
          -  Consumes excessive amounts, defined as more than 6 servings (1 serving is&#xD;
             approximately equivalent to 120 mg of caffeine) of coffee, tea, cola, energy drinks,&#xD;
             or other caffeinated beverages per day&#xD;
&#xD;
          -  Has a positive urine drug screen (except for cannabis) at screening and/or pre-dose;&#xD;
             rechecks are allowed&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>60 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Medical Director</last_name>
    <role>Study Director</role>
    <affiliation>Merck Sharp &amp; Dohme Corp.</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Charite Research Organisation GmbH ( Site 0001)</name>
      <address>
        <city>Berlin</city>
        <zip>10117</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Matei Bals Infectious Diseases Institute ( Site 0002)</name>
      <address>
        <city>Bucharest</city>
        <state>Bucuresti</state>
        <zip>021105</zip>
        <country>Romania</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Germany</country>
    <country>Romania</country>
  </location_countries>
  <verification_date>May 2021</verification_date>
  <study_first_submitted>February 28, 2019</study_first_submitted>
  <study_first_submitted_qc>February 28, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">March 1, 2019</study_first_posted>
  <results_first_submitted>May 5, 2021</results_first_submitted>
  <results_first_submitted_qc>May 5, 2021</results_first_submitted_qc>
  <results_first_posted type="Actual">May 28, 2021</results_first_posted>
  <last_update_submitted>May 5, 2021</last_update_submitted>
  <last_update_submitted_qc>May 5, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">May 28, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>http://engagezone.msd.com/doc/ProcedureAccessClinicalTrialData.pdf</ipd_description>
    <ipd_url>http://engagezone.msd.com/ds_documentation.php</ipd_url>
  </patient_data>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol and Statistical Analysis Plan</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>August 22, 2019</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/39/NCT03859739/Prot_SAP_000.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Participants with Human Immunodeficiency Virus Type 1 (HIV-1) infection, who were naïve to anti-retroviral therapy (ART) between 18 and 60 years old (inclusive) were enrolled in this study.</recruitment_details>
      <group_list>
        <group group_id="P1">
          <title>MK-8558 400 mg</title>
          <description>Single oral dose of MK-8558 administered at 400 mg following a 10-hour fast.</description>
        </group>
        <group group_id="P2">
          <title>MK-8558 900 mg</title>
          <description>Single oral dose of MK-8558 administered at 900 mg following a 10-hour fast.</description>
        </group>
        <group group_id="P3">
          <title>MK-8558 1600 mg</title>
          <description>Single oral dose of MK-8558 administered at 1600 mg following a 10-hour fast.</description>
        </group>
        <group group_id="P4">
          <title>MK-8558 900 mg Low-Fat</title>
          <description>Single oral dose of MK-8558 administered at 900 mg following a low-fat meal.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="5"/>
                <participants group_id="P2" count="6"/>
                <participants group_id="P3" count="6"/>
                <participants group_id="P4" count="4"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="5"/>
                <participants group_id="P2" count="6"/>
                <participants group_id="P3" count="6"/>
                <participants group_id="P4" count="4"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>MK-8558 400 mg</title>
          <description>Single oral dose of MK-8558 administered at 400 mg following a 10-hour fast.</description>
        </group>
        <group group_id="B2">
          <title>MK-8558 900 mg</title>
          <description>Single oral dose of MK-8558 administered at 900 mg following a 10-hour fast.</description>
        </group>
        <group group_id="B3">
          <title>MK-8558 1600 mg</title>
          <description>Single oral dose of MK-8558 administered at 1600 mg following a 10-hour fast.</description>
        </group>
        <group group_id="B4">
          <title>MK-8558 900 mg Low-Fat</title>
          <description>Single oral dose of MK-8558 administered at 900 mg following a low-fat meal.</description>
        </group>
        <group group_id="B5">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="5"/>
            <count group_id="B2" value="6"/>
            <count group_id="B3" value="6"/>
            <count group_id="B4" value="4"/>
            <count group_id="B5" value="21"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="29.2" spread="5.0"/>
                    <measurement group_id="B2" value="39.3" spread="12.6"/>
                    <measurement group_id="B3" value="32.5" spread="9.8"/>
                    <measurement group_id="B4" value="32.3" spread="18.6"/>
                    <measurement group_id="B5" value="33.6" spread="11.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="5"/>
                    <measurement group_id="B2" value="6"/>
                    <measurement group_id="B3" value="6"/>
                    <measurement group_id="B4" value="4"/>
                    <measurement group_id="B5" value="21"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Ethnicity (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="2"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="2"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Not Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="5"/>
                    <measurement group_id="B2" value="6"/>
                    <measurement group_id="B3" value="4"/>
                    <measurement group_id="B4" value="4"/>
                    <measurement group_id="B5" value="19"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="1"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="5"/>
                    <measurement group_id="B2" value="5"/>
                    <measurement group_id="B3" value="5"/>
                    <measurement group_id="B4" value="4"/>
                    <measurement group_id="B5" value="19"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Change From Baseline in Plasma HIV-1 Ribonucleic Acid (RNA) Concentration</title>
        <description>Plasma was collected at baseline and at 168 hours post-dose to determine the change from baseline in HIV-1 ribonucleic acid (RNA) concentration. The log10 plasma HIV-RNA was measured and analyzed based on a longitudinal data analysis (LDA) model containing fixed effects for dose level and time.</description>
        <time_frame>Baseline and 168 hours post-dose</time_frame>
        <population>Participants who comply with the protocol sufficiently to ensure that generated data will be likely to exhibit the effects of treatment, according to the underlying scientific model. One participant from the 900 mg treatment group was excluded from analysis due to important protocol deviation.</population>
        <group_list>
          <group group_id="O1">
            <title>MK-8558 400 mg</title>
            <description>Single oral dose of MK-8558 administered at 400 mg following a 10-hour fast.</description>
          </group>
          <group group_id="O2">
            <title>MK-8558 900 mg</title>
            <description>Single oral dose of MK-8558 administered at 900 mg following a 10-hour fast.</description>
          </group>
          <group group_id="O3">
            <title>MK-8558 1600 mg</title>
            <description>Single oral dose of MK-8558 administered at 1600 mg following a 10-hour fast.</description>
          </group>
          <group group_id="O4">
            <title>MK-8558 900 mg Low-Fat</title>
            <description>Single oral dose of MK-8558 administered at 900 mg following a low-fat meal.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Plasma HIV-1 Ribonucleic Acid (RNA) Concentration</title>
          <description>Plasma was collected at baseline and at 168 hours post-dose to determine the change from baseline in HIV-1 ribonucleic acid (RNA) concentration. The log10 plasma HIV-RNA was measured and analyzed based on a longitudinal data analysis (LDA) model containing fixed effects for dose level and time.</description>
          <population>Participants who comply with the protocol sufficiently to ensure that generated data will be likely to exhibit the effects of treatment, according to the underlying scientific model. One participant from the 900 mg treatment group was excluded from analysis due to important protocol deviation.</population>
          <units>log10 copies/mL</units>
          <param>Least Squares Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="5"/>
                <count group_id="O2" value="5"/>
                <count group_id="O3" value="6"/>
                <count group_id="O4" value="4"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.82" lower_limit="-1.42" upper_limit="-0.21"/>
                    <measurement group_id="O2" value="-1.00" lower_limit="-1.61" upper_limit="-0.39"/>
                    <measurement group_id="O3" value="-1.61" lower_limit="-2.16" upper_limit="-1.06"/>
                    <measurement group_id="O4" value="-1.81" lower_limit="-2.48" upper_limit="-1.13"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <groups_desc>It was hypothesized that the true mean difference in the plasma HIV-1 RNA reduction from baseline between MK-8558 and placebo is ≥ 1.4 log10 copies/mL.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <non_inferiority_desc>Adjusted by Placebo data pooled from historical placebo data from recent monotherapy studies in HIV-1 infected participants (NCT00100048, NCT01466985, NCT01152255, and NCT01353898) and fitted with a LDA model containing fixed effects for study and time, and a random effect for participants.</non_inferiority_desc>
            <param_type>Posterior Mean Difference</param_type>
            <param_value>-0.79</param_value>
            <estimate_desc>Posterior Probability (PP) of true mean difference in the plasma HIV-1 RNA change from baseline between MK-8558 and placebo ≤ -1.4 copies/mL was 2.44 %.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>It was hypothesized that the true mean difference in the plasma HIV-1 RNA reduction from baseline between MK-8558 and placebo is ≥ 1.4 log10 copies/mL.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <non_inferiority_desc>Adjusted by Placebo data pooled from historical placebo data from recent monotherapy studies in HIV-1 infected participants (NCT00100048, NCT01466985, NCT01152255, and NCT01353898) and fitted with a LDA model containing fixed effects for study and time, and a random effect for participants.</non_inferiority_desc>
            <param_type>Posterior Mean Difference</param_type>
            <param_value>-0.97</param_value>
            <estimate_desc>PP of true mean difference in the plasma HIV-1 RNA change from baseline between MK-8558 and placebo ≤ -1.4 copies/mL was 7.60%.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>It was hypothesized that the true mean difference in the plasma HIV-1 RNA reduction from baseline between MK-8558 and placebo is ≥ 1.4 log10 copies/mL.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <non_inferiority_desc>Adjusted by Placebo data pooled from historical placebo data from recent monotherapy studies in HIV-1 infected participants (NCT00100048, NCT01466985, NCT01152255, and NCT01353898) and fitted with a LDA model containing fixed effects for study and time, and a random effect for participants.</non_inferiority_desc>
            <param_type>Posterior Mean Difference</param_type>
            <param_value>-1.58</param_value>
            <estimate_desc>PP of true mean difference in the plasma HIV-1 RNA change from baseline between MK-8558 and placebo ≤ -1.4 copies/mL was 74.99%.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>It was hypothesized that the true mean difference in the plasma HIV-1 RNA reduction from baseline between MK-8558 and placebo is ≥ 1.4 log10 copies/mL.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <non_inferiority_desc>Adjusted by Placebo data pooled from historical placebo data from recent monotherapy studies in HIV-1 infected participants (NCT00100048, NCT01466985, NCT01152255, and NCT01353898) and fitted with a LDA model containing fixed effects for study and time, and a random effect for participants.</non_inferiority_desc>
            <param_type>Posterior Mean Difference</param_type>
            <param_value>-1.78</param_value>
            <estimate_desc>PP of true mean difference in the plasma HIV-1 RNA change from baseline between MK-8558 and placebo ≤ -1.4 copies/mL was 87.41%.</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Number of Participants Experiencing ≥1 Adverse Event (AE)</title>
        <description>An Adverse Event (AE) is any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. An AE can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease (new or exacerbated) temporally associated with the use of a study intervention.</description>
        <time_frame>Up to 35 days post-dose</time_frame>
        <population>All participants who received at least one dose of treatment.</population>
        <group_list>
          <group group_id="O1">
            <title>MK-8558 400 mg</title>
            <description>Single oral dose of MK-8558 administered at 400 mg following a 10-hour fast.</description>
          </group>
          <group group_id="O2">
            <title>MK-8558 900 mg</title>
            <description>Single oral dose of MK-8558 administered at 900 mg following a 10-hour fast.</description>
          </group>
          <group group_id="O3">
            <title>MK-8558 1600 mg</title>
            <description>Single oral dose of MK-8558 administered at 1600 mg following a 10-hour fast.</description>
          </group>
          <group group_id="O4">
            <title>MK-8558 900 mg Low-Fat</title>
            <description>Single oral dose of MK-8558 administered at 900 mg following a low-fat meal.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants Experiencing ≥1 Adverse Event (AE)</title>
          <description>An Adverse Event (AE) is any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. An AE can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease (new or exacerbated) temporally associated with the use of a study intervention.</description>
          <population>All participants who received at least one dose of treatment.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="5"/>
                <count group_id="O2" value="6"/>
                <count group_id="O3" value="6"/>
                <count group_id="O4" value="4"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4"/>
                    <measurement group_id="O2" value="3"/>
                    <measurement group_id="O3" value="4"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Number of Participants Who Discontinued From the Study Due to an AE</title>
        <description>An AE is any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. An AE can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease (new or exacerbated) temporally associated with the use of a study intervention.</description>
        <time_frame>Up to 35 days post-dose</time_frame>
        <population>All participants who received at least one dose of treatment</population>
        <group_list>
          <group group_id="O1">
            <title>MK-8558 400 mg</title>
            <description>Single oral dose of MK-8558 administered at 400 mg following a 10-hour fast.</description>
          </group>
          <group group_id="O2">
            <title>MK-8558 900 mg</title>
            <description>Single oral dose of MK-8558 administered at 900 mg following a 10-hour fast.</description>
          </group>
          <group group_id="O3">
            <title>MK-8558 1600 mg</title>
            <description>Single oral dose of MK-8558 administered at 1600 mg following a 10-hour fast.</description>
          </group>
          <group group_id="O4">
            <title>MK-8558 900 mg Low-Fat</title>
            <description>Single oral dose of MK-8558 administered at 900 mg following a low-fat meal.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants Who Discontinued From the Study Due to an AE</title>
          <description>An AE is any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. An AE can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease (new or exacerbated) temporally associated with the use of a study intervention.</description>
          <population>All participants who received at least one dose of treatment</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="5"/>
                <count group_id="O2" value="6"/>
                <count group_id="O3" value="6"/>
                <count group_id="O4" value="4"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Area Under the Concentration-Time Curve From 0 to 168 Hours (AUC0-168) for MK-8558 in Plasma</title>
        <description>Plasma was collected from pre-dose up to 168 hours post-dose in order to determine the AUC0-168 for MK-8558. Data were natural log transformed and analyzed based on a linear model containing a fixed effect for dose level.</description>
        <time_frame>Pre-dose and 0.5, 1, 1.5, 2, 3, 4, 5, 6, 8, 12, 24, 48, 72, 120, 168 hours post-dose</time_frame>
        <population>Participants who comply with the protocol sufficiently to ensure that generated data will be likely to exhibit the effects of treatment, according to the underlying scientific model. One participant from the 900 mg treatment group was excluded from analysis due to important protocol deviation.</population>
        <group_list>
          <group group_id="O1">
            <title>MK-8558 400 mg</title>
            <description>Single oral dose of MK-8558 administered at 400 mg following a 10-hour fast.</description>
          </group>
          <group group_id="O2">
            <title>MK-8558 900 mg</title>
            <description>Single oral dose of MK-8558 administered at 900 mg following a 10-hour fast.</description>
          </group>
          <group group_id="O3">
            <title>MK-8558 1600 mg</title>
            <description>Single oral dose of MK-8558 administered at 1600 mg following a 10-hour fast.</description>
          </group>
          <group group_id="O4">
            <title>MK-8558 900 mg Low-Fat</title>
            <description>Single oral dose of MK-8558 administered at 900 mg following a low-fat meal.</description>
          </group>
        </group_list>
        <measure>
          <title>Area Under the Concentration-Time Curve From 0 to 168 Hours (AUC0-168) for MK-8558 in Plasma</title>
          <description>Plasma was collected from pre-dose up to 168 hours post-dose in order to determine the AUC0-168 for MK-8558. Data were natural log transformed and analyzed based on a linear model containing a fixed effect for dose level.</description>
          <population>Participants who comply with the protocol sufficiently to ensure that generated data will be likely to exhibit the effects of treatment, according to the underlying scientific model. One participant from the 900 mg treatment group was excluded from analysis due to important protocol deviation.</population>
          <units>hr*μM</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="5"/>
                <count group_id="O2" value="5"/>
                <count group_id="O3" value="6"/>
                <count group_id="O4" value="4"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1740" spread="24.2"/>
                    <measurement group_id="O2" value="2780" spread="20.7"/>
                    <measurement group_id="O3" value="5740" spread="36.3"/>
                    <measurement group_id="O4" value="5340" spread="15.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Area Under the Concentration-Time Curve From 0 up to the Last Quantifiable Time-Point (AUC0-last) for MK-8558 in Plasma</title>
        <description>Plasma was collected from pre-dose up to 504 hours post-dose in order to determine the AUC0-last for MK-8558. Data were natural log transformed and analyzed based on a linear model containing a fixed effect for dose level.</description>
        <time_frame>Pre-dose and 0.5, 1, 1.5, 2, 3, 4, 5, 6, 8, 12, 24, 48, 72, 120, 168, 240, 336, 504 hours post-dose</time_frame>
        <population>Participants who comply with the protocol sufficiently to ensure that generated data will be likely to exhibit the effects of treatment, according to the underlying scientific model. One participant from the 900 mg treatment group was excluded from analysis due to important protocol deviation.</population>
        <group_list>
          <group group_id="O1">
            <title>MK-8558 400 mg</title>
            <description>Single oral dose of MK-8558 administered at 400 mg following a 10-hour fast.</description>
          </group>
          <group group_id="O2">
            <title>MK-8558 900 mg</title>
            <description>Single oral dose of MK-8558 administered at 900 mg following a 10-hour fast.</description>
          </group>
          <group group_id="O3">
            <title>MK-8558 1600 mg</title>
            <description>Single oral dose of MK-8558 administered at 1600 mg following a 10-hour fast.</description>
          </group>
          <group group_id="O4">
            <title>MK-8558 900 mg Low-Fat</title>
            <description>Single oral dose of MK-8558 administered at 900 mg following a low-fat meal.</description>
          </group>
        </group_list>
        <measure>
          <title>Area Under the Concentration-Time Curve From 0 up to the Last Quantifiable Time-Point (AUC0-last) for MK-8558 in Plasma</title>
          <description>Plasma was collected from pre-dose up to 504 hours post-dose in order to determine the AUC0-last for MK-8558. Data were natural log transformed and analyzed based on a linear model containing a fixed effect for dose level.</description>
          <population>Participants who comply with the protocol sufficiently to ensure that generated data will be likely to exhibit the effects of treatment, according to the underlying scientific model. One participant from the 900 mg treatment group was excluded from analysis due to important protocol deviation.</population>
          <units>hr*μM</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="5"/>
                <count group_id="O2" value="5"/>
                <count group_id="O3" value="6"/>
                <count group_id="O4" value="4"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2650" spread="32.9"/>
                    <measurement group_id="O2" value="4450" spread="16.2"/>
                    <measurement group_id="O3" value="9680" spread="42.6"/>
                    <measurement group_id="O4" value="8580" spread="9.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Area Under the Concentration-Time Curve From 0 to Infinity (AUC0-inf) for MK-8558 in Plasma</title>
        <description>Plasma was collected from pre-dose up to 504 hours post-dose in order to determine the AUC0-inf for MK-8558. Data were natural log transformed and analyzed based on a linear model containing a fixed effect for dose level.</description>
        <time_frame>Pre-dose and 0.5, 1, 1.5, 2, 3, 4, 5, 6, 8, 12, 24, 48, 72, 120, 168, 240, 336, 504 hours post-dose</time_frame>
        <population>Participants who comply with the protocol sufficiently to ensure that generated data will be likely to exhibit the effects of treatment, according to the underlying scientific model. One participant from the 900 mg treatment group was excluded from analysis due to important protocol deviation.</population>
        <group_list>
          <group group_id="O1">
            <title>MK-8558 400 mg</title>
            <description>Single oral dose of MK-8558 administered at 400 mg following a 10-hour fast.</description>
          </group>
          <group group_id="O2">
            <title>MK-8558 900 mg</title>
            <description>Single oral dose of MK-8558 administered at 900 mg following a 10-hour fast.</description>
          </group>
          <group group_id="O3">
            <title>MK-8558 1600 mg</title>
            <description>Single oral dose of MK-8558 administered at 1600 mg following a 10-hour fast.</description>
          </group>
          <group group_id="O4">
            <title>MK-8558 900 mg Low-Fat</title>
            <description>Single oral dose of MK-8558 administered at 900 mg following a low-fat meal.</description>
          </group>
        </group_list>
        <measure>
          <title>Area Under the Concentration-Time Curve From 0 to Infinity (AUC0-inf) for MK-8558 in Plasma</title>
          <description>Plasma was collected from pre-dose up to 504 hours post-dose in order to determine the AUC0-inf for MK-8558. Data were natural log transformed and analyzed based on a linear model containing a fixed effect for dose level.</description>
          <population>Participants who comply with the protocol sufficiently to ensure that generated data will be likely to exhibit the effects of treatment, according to the underlying scientific model. One participant from the 900 mg treatment group was excluded from analysis due to important protocol deviation.</population>
          <units>hr*μM</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="5"/>
                <count group_id="O2" value="5"/>
                <count group_id="O3" value="6"/>
                <count group_id="O4" value="4"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2840" spread="37.3"/>
                    <measurement group_id="O2" value="4870" spread="14.7"/>
                    <measurement group_id="O3" value="11100" spread="48.9"/>
                    <measurement group_id="O4" value="9520" spread="9.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Maximum Observed Concentration (Cmax) for MK-8558 in Plasma</title>
        <description>Plasma was collected from pre-dose up to 504 hours post-dose in order to determine the Cmax for MK-8558. Data were natural log transformed and analyzed based on a linear model containing a fixed effect for dose level.</description>
        <time_frame>Pre-dose and 0.5, 1, 1.5, 2, 3, 4, 5, 6, 8, 12, 24, 48, 72, 120, 168, 240, 336, 504 hours post-dose</time_frame>
        <population>Participants who comply with the protocol sufficiently to ensure that generated data will be likely to exhibit the effects of treatment, according to the underlying scientific model. One participant from the 900 mg treatment group was excluded from analysis due to important protocol deviation.</population>
        <group_list>
          <group group_id="O1">
            <title>MK-8558 400 mg</title>
            <description>Single oral dose of MK-8558 administered at 400 mg following a 10-hour fast.</description>
          </group>
          <group group_id="O2">
            <title>MK-8558 900 mg</title>
            <description>Single oral dose of MK-8558 administered at 900 mg following a 10-hour fast.</description>
          </group>
          <group group_id="O3">
            <title>MK-8558 1600 mg</title>
            <description>Single oral dose of MK-8558 administered at 1600 mg following a 10-hour fast.</description>
          </group>
          <group group_id="O4">
            <title>MK-8558 900 mg Low-Fat</title>
            <description>Single oral dose of MK-8558 administered at 900 mg following a low-fat meal.</description>
          </group>
        </group_list>
        <measure>
          <title>Maximum Observed Concentration (Cmax) for MK-8558 in Plasma</title>
          <description>Plasma was collected from pre-dose up to 504 hours post-dose in order to determine the Cmax for MK-8558. Data were natural log transformed and analyzed based on a linear model containing a fixed effect for dose level.</description>
          <population>Participants who comply with the protocol sufficiently to ensure that generated data will be likely to exhibit the effects of treatment, according to the underlying scientific model. One participant from the 900 mg treatment group was excluded from analysis due to important protocol deviation.</population>
          <units>μM</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="5"/>
                <count group_id="O2" value="5"/>
                <count group_id="O3" value="6"/>
                <count group_id="O4" value="4"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="24.3" spread="21.7"/>
                    <measurement group_id="O2" value="36.7" spread="28.9"/>
                    <measurement group_id="O3" value="77.2" spread="28.9"/>
                    <measurement group_id="O4" value="72.6" spread="14.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Time to Maximum Observed Concentration (Tmax) for MK-8558 in Plasma</title>
        <description>Plasma was collected from pre-dose up to 504 hours post-dose in order to determine the Tmax for MK-8558. Data were natural log transformed and analyzed based on a linear model containing a fixed effect for dose level.</description>
        <time_frame>Pre-dose and 0.5, 1, 1.5, 2, 3, 4, 5, 6, 8, 12, 24, 48, 72, 120, 168, 240, 336, 504 hours post-dose</time_frame>
        <population>Participants who comply with the protocol sufficiently to ensure that generated data will be likely to exhibit the effects of treatment, according to the underlying scientific model. One participant from the 900 mg treatment group was excluded from analysis due to important protocol deviation.</population>
        <group_list>
          <group group_id="O1">
            <title>MK-8558 400 mg</title>
            <description>Single oral dose of MK-8558 administered at 400 mg following a 10-hour fast.</description>
          </group>
          <group group_id="O2">
            <title>MK-8558 900 mg</title>
            <description>Single oral dose of MK-8558 administered at 900 mg following a 10-hour fast.</description>
          </group>
          <group group_id="O3">
            <title>MK-8558 1600 mg</title>
            <description>Single oral dose of MK-8558 administered at 1600 mg following a 10-hour fast.</description>
          </group>
          <group group_id="O4">
            <title>MK-8558 900 mg Low-Fat</title>
            <description>Single oral dose of MK-8558 administered at 900 mg following a low-fat meal.</description>
          </group>
        </group_list>
        <measure>
          <title>Time to Maximum Observed Concentration (Tmax) for MK-8558 in Plasma</title>
          <description>Plasma was collected from pre-dose up to 504 hours post-dose in order to determine the Tmax for MK-8558. Data were natural log transformed and analyzed based on a linear model containing a fixed effect for dose level.</description>
          <population>Participants who comply with the protocol sufficiently to ensure that generated data will be likely to exhibit the effects of treatment, according to the underlying scientific model. One participant from the 900 mg treatment group was excluded from analysis due to important protocol deviation.</population>
          <units>Hours</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="5"/>
                <count group_id="O2" value="5"/>
                <count group_id="O3" value="6"/>
                <count group_id="O4" value="4"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.00" lower_limit="1.50" upper_limit="4.00"/>
                    <measurement group_id="O2" value="4.00" lower_limit="4.00" upper_limit="5.00"/>
                    <measurement group_id="O3" value="4.50" lower_limit="4.00" upper_limit="8.02"/>
                    <measurement group_id="O4" value="4.02" lower_limit="4.00" upper_limit="5.00"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Concentration at 168 Hours Post-Dose (C168hr) for MK-8558 in Plasma</title>
        <description>Plasma was collected at 168 hours post-dose in order to determine the C168hr for MK-8558. Data were natural log transformed and analyzed based on a linear model containing a fixed effect for dose level.</description>
        <time_frame>168 hours post-dose</time_frame>
        <population>Participants who comply with the protocol sufficiently to ensure that generated data will be likely to exhibit the effects of treatment, according to the underlying scientific model. One participant from the 900 mg treatment group was excluded from analysis due to important protocol deviation.</population>
        <group_list>
          <group group_id="O1">
            <title>MK-8558 400 mg</title>
            <description>Single oral dose of MK-8558 administered at 400 mg following a 10-hour fast.</description>
          </group>
          <group group_id="O2">
            <title>MK-8558 900 mg</title>
            <description>Single oral dose of MK-8558 administered at 900 mg following a 10-hour fast.</description>
          </group>
          <group group_id="O3">
            <title>MK-8558 1600 mg</title>
            <description>Single oral dose of MK-8558 administered at 1600 mg following a 10-hour fast.</description>
          </group>
          <group group_id="O4">
            <title>MK-8558 900 mg Low-Fat</title>
            <description>Single oral dose of MK-8558 administered at 900 mg following a low-fat meal.</description>
          </group>
        </group_list>
        <measure>
          <title>Concentration at 168 Hours Post-Dose (C168hr) for MK-8558 in Plasma</title>
          <description>Plasma was collected at 168 hours post-dose in order to determine the C168hr for MK-8558. Data were natural log transformed and analyzed based on a linear model containing a fixed effect for dose level.</description>
          <population>Participants who comply with the protocol sufficiently to ensure that generated data will be likely to exhibit the effects of treatment, according to the underlying scientific model. One participant from the 900 mg treatment group was excluded from analysis due to important protocol deviation.</population>
          <units>μM</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="5"/>
                <count group_id="O2" value="5"/>
                <count group_id="O3" value="6"/>
                <count group_id="O4" value="4"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.59" spread="44.0"/>
                    <measurement group_id="O2" value="9.55" spread="17.7"/>
                    <measurement group_id="O3" value="20.5" spread="43.4"/>
                    <measurement group_id="O4" value="18.8" spread="8.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <groups_desc>The posterior probability (PP) that the true GM C168hr is ≥ 9.0 μM was calculated using a non-informative (Jeffrey's) prior under an assumption of normality of log C168hr.</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <param_type>Standard Error (SE)</param_type>
            <param_value>0.146</param_value>
            <estimate_desc>PP that the true C168hr in plasma MK-8558 is ≥ 9.0 μM was 0.25%.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>The PP that the true GM C168hr is ≥ 9.0 μM was calculated using a non-informative (Jeffrey's) prior under an assumption of normality of log C168hr.</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <param_type>SE</param_type>
            <param_value>0.146</param_value>
            <estimate_desc>PP that the true C168hr in plasma MK-8558 is ≥ 9.0 μM was 65.41%.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>The PP that the true GM C168hr is ≥ 9.0 μM was calculated using a non-informative (Jeffrey's) prior under an assumption of normality of log C168hr.</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <param_type>SE</param_type>
            <param_value>0.133</param_value>
            <estimate_desc>PP that the true C168hr in plasma MK-8558 is ≥ 9.0 μM was 99.99%.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>The PP that the true GM C168hr is ≥ 9.0 μM was calculated using a non-informative (Jeffrey's) prior under an assumption of normality of log C168hr.</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <param_type>SE</param_type>
            <param_value>0.163</param_value>
            <estimate_desc>PP that the true C168hr in plasma MK-8558 is ≥ 9.0 μM was 99.98%.</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Apparent Clearance (CL/F) for MK-8558</title>
        <description>Plasma was collected from pre-dose up to 504 hours post-dose in order to determine the CL/F for MK-8558. Data were natural log transformed and analyzed based on a linear model containing a fixed effect for dose level.</description>
        <time_frame>Pre-dose and 0.5, 1, 1.5, 2, 3, 4, 5, 6, 8, 12, 24, 48, 72, 120, 168, 240, 336, 504 hours post-dose</time_frame>
        <population>Participants who comply with the protocol sufficiently to ensure that generated data will be likely to exhibit the effects of treatment, according to the underlying scientific model. One participant from the 900 mg treatment group was excluded from analysis due to important protocol deviation.</population>
        <group_list>
          <group group_id="O1">
            <title>MK-8558 400 mg</title>
            <description>Single oral dose of MK-8558 administered at 400 mg following a 10-hour fast.</description>
          </group>
          <group group_id="O2">
            <title>MK-8558 900 mg</title>
            <description>Single oral dose of MK-8558 administered at 900 mg following a 10-hour fast.</description>
          </group>
          <group group_id="O3">
            <title>MK-8558 1600 mg</title>
            <description>Single oral dose of MK-8558 administered at 1600 mg following a 10-hour fast.</description>
          </group>
          <group group_id="O4">
            <title>MK-8558 900 mg Low-Fat</title>
            <description>Single oral dose of MK-8558 administered at 900 mg following a low-fat meal.</description>
          </group>
        </group_list>
        <measure>
          <title>Apparent Clearance (CL/F) for MK-8558</title>
          <description>Plasma was collected from pre-dose up to 504 hours post-dose in order to determine the CL/F for MK-8558. Data were natural log transformed and analyzed based on a linear model containing a fixed effect for dose level.</description>
          <population>Participants who comply with the protocol sufficiently to ensure that generated data will be likely to exhibit the effects of treatment, according to the underlying scientific model. One participant from the 900 mg treatment group was excluded from analysis due to important protocol deviation.</population>
          <units>L/hr</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="5"/>
                <count group_id="O2" value="5"/>
                <count group_id="O3" value="6"/>
                <count group_id="O4" value="4"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.315" spread="37.3"/>
                    <measurement group_id="O2" value="0.412" spread="14.7"/>
                    <measurement group_id="O3" value="0.321" spread="48.9"/>
                    <measurement group_id="O4" value="0.211" spread="9.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Apparent Volume of Distribution (Vz/F) for MK-8558</title>
        <description>Plasma was collected from pre-dose up to 504 hours post-dose in order to determine the Vz/F for MK-8558. Data were natural log transformed and analyzed based on a linear model containing a fixed effect for dose level.</description>
        <time_frame>Pre-dose and 0.5, 1, 1.5, 2, 3, 4, 5, 6, 8, 12, 24, 48, 72, 120, 168, 240, 336, 504 hours post-dose</time_frame>
        <population>Participants who comply with the protocol sufficiently to ensure that generated data will be likely to exhibit the effects of treatment, according to the underlying scientific model. One participant from the 900 mg treatment group was excluded from analysis due to important protocol deviation.</population>
        <group_list>
          <group group_id="O1">
            <title>MK-8558 400 mg</title>
            <description>Single oral dose of MK-8558 administered at 400 mg following a 10-hour fast.</description>
          </group>
          <group group_id="O2">
            <title>MK-8558 900 mg</title>
            <description>Single oral dose of MK-8558 administered at 900 mg following a 10-hour fast.</description>
          </group>
          <group group_id="O3">
            <title>MK-8558 1600 mg</title>
            <description>Single oral dose of MK-8558 administered at 1600 mg following a 10-hour fast.</description>
          </group>
          <group group_id="O4">
            <title>MK-8558 900 mg Low-Fat</title>
            <description>Single oral dose of MK-8558 administered at 900 mg following a low-fat meal.</description>
          </group>
        </group_list>
        <measure>
          <title>Apparent Volume of Distribution (Vz/F) for MK-8558</title>
          <description>Plasma was collected from pre-dose up to 504 hours post-dose in order to determine the Vz/F for MK-8558. Data were natural log transformed and analyzed based on a linear model containing a fixed effect for dose level.</description>
          <population>Participants who comply with the protocol sufficiently to ensure that generated data will be likely to exhibit the effects of treatment, according to the underlying scientific model. One participant from the 900 mg treatment group was excluded from analysis due to important protocol deviation.</population>
          <units>Liters</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="5"/>
                <count group_id="O2" value="5"/>
                <count group_id="O3" value="6"/>
                <count group_id="O4" value="4"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="56.6" spread="21.9"/>
                    <measurement group_id="O2" value="84.4" spread="27.5"/>
                    <measurement group_id="O3" value="79.9" spread="30.8"/>
                    <measurement group_id="O4" value="45.6" spread="20.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Terminal Half Life (t1/2) for MK-8558</title>
        <description>Plasma was collected from pre-dose up to 504 hours post-dose in order to determine the t1/2 for MK-8558. Data were natural log transformed and analyzed based on a linear model containing a fixed effect for dose level.</description>
        <time_frame>Pre-dose and 0.5, 1, 1.5, 2, 3, 4, 5, 6, 8, 12, 24, 48, 72, 120, 168, 240, 336, 504 hours post-dose</time_frame>
        <population>Participants who comply with the protocol sufficiently to ensure that generated data will be likely to exhibit the effects of treatment, according to the underlying scientific model. One participant from the 900 mg treatment group was excluded from analysis due to important protocol deviation.</population>
        <group_list>
          <group group_id="O1">
            <title>MK-8558 400 mg</title>
            <description>Single oral dose of MK-8558 administered at 400 mg following a 10-hour fast.</description>
          </group>
          <group group_id="O2">
            <title>MK-8558 900 mg</title>
            <description>Single oral dose of MK-8558 administered at 900 mg following a 10-hour fast.</description>
          </group>
          <group group_id="O3">
            <title>MK-8558 1600 mg</title>
            <description>Single oral dose of MK-8558 administered at 1600 mg following a 10-hour fast.</description>
          </group>
          <group group_id="O4">
            <title>MK-8558 900 mg Low-Fat</title>
            <description>Single oral dose of MK-8558 administered at 900 mg following a low-fat meal.</description>
          </group>
        </group_list>
        <measure>
          <title>Terminal Half Life (t1/2) for MK-8558</title>
          <description>Plasma was collected from pre-dose up to 504 hours post-dose in order to determine the t1/2 for MK-8558. Data were natural log transformed and analyzed based on a linear model containing a fixed effect for dose level.</description>
          <population>Participants who comply with the protocol sufficiently to ensure that generated data will be likely to exhibit the effects of treatment, according to the underlying scientific model. One participant from the 900 mg treatment group was excluded from analysis due to important protocol deviation.</population>
          <units>Hours</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="5"/>
                <count group_id="O2" value="5"/>
                <count group_id="O3" value="6"/>
                <count group_id="O4" value="4"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="125" spread="24.9"/>
                    <measurement group_id="O2" value="142" spread="20.1"/>
                    <measurement group_id="O3" value="173" spread="22.7"/>
                    <measurement group_id="O4" value="150" spread="20.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Adverse events: Up to 35 days post-dose; All-cause mortality: Up to 9 weeks after randomization.</time_frame>
      <desc>All participants who received at least one dose of treatment.</desc>
      <group_list>
        <group group_id="E1">
          <title>MK-8558 400 mg</title>
          <description>Single oral dose of MK-8558 administered at 400 mg following a 10-hour fast.</description>
        </group>
        <group group_id="E2">
          <title>MK-8558 900 mg</title>
          <description>Single oral dose of MK-8558 administered at 900 mg following a 10-hour fast.</description>
        </group>
        <group group_id="E3">
          <title>MK-8558 1600 mg</title>
          <description>Single oral dose of MK-8558 administered at 1600 mg following a 10-hour fast.</description>
        </group>
        <group group_id="E4">
          <title>MK-8558 900 mg Low-Fat</title>
          <description>Single oral dose of MK-8558 administered at 900 mg following a low-fat meal.</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA 23.0</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="4"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="5"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="4"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Enteritis infectious</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="4"/>
              </event>
              <event>
                <sub_title>Pharyngotonsillitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="5"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="4"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Rash maculo-papular</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="4"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_vocab>MedDRA 23.0</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="5"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="6"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="4"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Aphthous ulcer</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="4"/>
              </event>
              <event>
                <sub_title>Diarrhoea</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="6"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="4"/>
              </event>
              <event>
                <sub_title>Dyspepsia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="5"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="4"/>
              </event>
              <event>
                <sub_title>Gastritis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="4"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Fatigue</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="4"/>
              </event>
              <event>
                <sub_title>Pyrexia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="4"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Epstein-Barr virus infection</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="4"/>
              </event>
              <event>
                <sub_title>Nasopharyngitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="5"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="6"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="4"/>
              </event>
              <event>
                <sub_title>Pharyngotonsillitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="5"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="4"/>
              </event>
              <event>
                <sub_title>Tonsillitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="4"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Decreased appetite</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="4"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Arthritis reactive</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="5"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="4"/>
              </event>
              <event>
                <sub_title>Myalgia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="5"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="4"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="5"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="4"/>
              </event>
              <event>
                <sub_title>Paraesthesia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="4"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Middle insomnia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="4"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Cough</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="4"/>
              </event>
              <event>
                <sub_title>Oropharyngeal pain</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="5"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="4"/>
              </event>
              <event>
                <sub_title>Rhinorrhoea</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="4"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Rash</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="4"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>If publication activity is not directed by the Sponsor, the investigator agrees to submit all manuscripts or abstracts to the Sponsor before submission.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Senior Vice President, Global Clinical Development</name_or_title>
      <organization>Merck Sharp &amp; Dohme Corp.</organization>
      <phone>1-800-672-6372</phone>
      <email>ClinicalTrialsDisclosure@merck.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

